Tolerogenic peptides from myelin basic protein
AssigneeApitope Technology (Bristol) Limited
InventorsDavid Cameron Wraith, Heather Barbara Streeter, Mary Ponsford, Graziella Mazza
Life of this patent
Estimating the term…
Abstract
There is provided a peptide that is capable of binding to an MHC class I or II molecule without further processing (i.e., an apitope), which comprises a portion of the region 131-158 of myelin basic protein. In particular, there is provided an apitope which is selected from the following myelin basic protein peptides: 134-148, 135-149, 136-150, 137-151, 138-152, 139-153, 140-154. There is also provided the use of such a peptide in a pharmaceutical composition and a method to treat and/or prevent a disease using such a peptide.
Claims16
An isolated and purified peptide consisting of the sequence SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6 or SEQ ID NO:7.
A therapeutic composition comprising an effective, immunosuppressive amount of an isolated and purified peptide consisting of the sequence SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6 or SEQ ID NO:7.
A method for treating or preventing multiple sclerosis in a subject in need thereof comprising administering to the subject an effective amount of an isolated and purified peptide consisting of SEQ ID NO:7.
Dependencies are inferred from the claim text.